|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
CTD_human |
Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving beta-catenin, c-Myc and E2F1.
|
17404573 |
2007 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Bcl-XL, an anti-apoptotic protein of Bcl-2 family, is overexpressed in colon cancers.
|
17534896 |
2007 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Collectively, our results revealed that ZEB2-AS1 was upregualted and functioned as an oncogene via regulating miR-143/bcl-2 axis in colon cancer.
|
31497237 |
2019 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of Bcl2 expression might represent a potential mechanism by which ASA induces apoptosis in this COX-2 negative colon cancer cell line.
|
12423325 |
2002 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Emodin activated caspases, modulated Bcl-2 family of proteins and reduced mitochondrial membrane potential to induce CoCa cell death.
|
31011292 |
2019 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Exosome-Carried microRNA-375 Inhibits Cell Progression and Dissemination via Bcl-2 Blocking in Colon Cancer.
|
26697569 |
2015 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression of cell survival/death genes: Bcl-2 and Bax at the rate of colon cancer prognosis.
|
15955446 |
2005 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
CTD_human |
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.
|
19147571 |
2009 |
|
Malignant tumor of colon
|
0.600 |
Therapeutic
|
disease |
RGD |
High energy shock waves and 5-aminolevulinic for sonodynamic therapy: effects in a syngeneic model of colon cancer.
|
21214291 |
2011 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
High expressions of Bag-1 and Bcl-2 proteins in colon cancer were found.
|
20409521 |
2010 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
In both the uninvolved MIN mouse colonic epithelium and HT-29 colon cancer cells, nabumetone downregulated the anti-apoptotic protein, Bcl-2, with concomitant induction of apoptosis, suggesting a potential mechanism for colon cancer chemoprevention.
|
11355956 |
2001 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In particular, the PC-loaded EFM exerted its anti-cancer activity by blocking the cell cycle at the G0/G1 phase and inducing cell apoptosis involving the decrease of Bcl-2/Bax, activation of caspase 3 and release of cytochrome c. This study suggests that co-axial electrospinning is an efficient and effective way to deliver PC and improve its bioavailability; thus, it represents a promising approach for encapsulating functional ingredients for colon cancer prevention.
|
30806395 |
2019 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of bcl-2 is seen in a population of colon cancer cells resistant to PYY.
|
10612539 |
1999 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Other studies have suggested an inverse relationship between p53 and bcl-2 protein expression in breast and colonic cancers and in a variety of subtypes of non-Hodgkin's lymphoma.
|
9349233 |
1997 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that early apoptosis and cell death of human colon cancer cells induced by photodynamic therapy with lysosome-localizing photosensitizer ATX-S10Na (II) are mediated by p53-Bax network and low levels of Bcl-2 and Bcl-x(L) proteins.
|
17278191 |
2007 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
CTD_human |
Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice.
|
10223192 |
1999 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status.
|
11920608 |
2002 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
|
25548100 |
2015 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Silencing of miR-210 upregulated Bcl-2 expression and reduced the survival fraction of colon cancer cells after radiation treatment.
|
25385144 |
2015 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.
|
17426704 |
2007 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Targeting Bcl-2 proteins via DZNep or BH3 mimetics could increase the therapeutic potential of MDM2-antagonists like Nutlin-3a in colon cancer.
|
29394130 |
2018 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expressions of C-MYC and BCL-2 in colon cancer tissues exhibited high levels of expression, while miR-184 displayed relatively low levels in comparison to the adjacent normal tissues.
|
28782841 |
2018 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The loss of Bcl-2 expression appears to be correlated with increase in number of relapses in the stage II colon cancers and could be a potential useful additional histo-prognostic marker in therapy decision making.
|
19027288 |
2009 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study aimed to explore the role of B-cell lymphoma 2 (BCL-2) in promoting colon cancer development associated with LIN28B.
|
29669301 |
2018 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
There may be a therapeutic window for taxanes in colon cancer by optimizing pharmacokinetics and modulating MDR-1 and bcl-2 resistance factors.
|
11052631 |
2000 |